Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Bactiguard Holding AB's 9-Day RSI or its related term are showing as below:
LTS:0QV2's 9-Day RSI is ranked better than 65.28% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 45.51
vs LTS:0QV2: 97.42
Bactiguard Holding AB (LTS:0QV2) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Bactiguard Holding AB 9-Day RSI Related Terms
LTS:0QV2 vs ABT, SYK, MDT: 9-Day RSI Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's 9-Day RSI falls into.
Bactiguard Holding AB (LTS:0QV2) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (LTS:0QV2) has a 9-Day RSI of 97.42 as of Jul. 21, 2026. According to the industry distribution chart, Bactiguard Holding AB ranks #301 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 34.7%.
Is Bactiguard Holding AB's 9-Day RSI too high?
Bactiguard Holding AB's current 9-Day RSI is 97.42. The Medical Devices & Instruments industry median 9-Day RSI is 45.51. Bactiguard Holding AB's value of 97.42 is 114.1% above this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #301 out of 867 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bactiguard Holding AB has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's 9-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #301 out of 867 companies for 9-Day RSI. This puts Bactiguard Holding AB in the upper half of its industry. The industry median 9-Day RSI is 45.51. Bactiguard Holding AB's value of 97.42 is 114.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 45.51, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current 9-Day RSI of 97.42 is 114.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 45.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current 9-Day RSI is 97.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (LTS:0QV2) has a current 9-Day RSI of 97.42. The stock's GF Value™ is kr34.17, compared to a current price of kr17.25 — trading 49.5% below its estimated fair value. The current 9-Day RSI is 97.42 and 114.1% above the Medical Devices & Instruments industry median of 45.51. Bactiguard Holding AB's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Bactiguard Holding AB (LTS:0QV2), the current 9-Day RSI is 97.42 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (LTS:0QV2) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr17.25 is trading 49.5% below its estimated GF Value™ of kr34.17.
Key valuation signals for LTS:0QV2:
9-Day RSI: 97.42
GF Value™: kr34.17 vs. price of kr17.25 (49.5% below fair value)
Industry Position: 114.1% above the Medical Devices & Instruments median (#301 of 867)
No single metric tells the full story. See the LTS:0QV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
61GF Score
Get the complete analysis for LTS:0QV2
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QV2 has been successfully added to your 
